CONMED Corporation 2019 Form 10-K Summary
Business context and reporting period
CONMED is a medical technology company providing surgical devices and equipment for minimally invasive procedures in orthopedic and general surgery. The filing covers the fiscal year ended December 31, 2019; the requested “2019 Q4” information is presented as part of the annual filing and includes fourth-quarter data where disclosed. The Company had approximately 3,300 employees, sold products in more than 100 countries, and generated approximately 46% of consolidated sales from customers outside the United States.
Products are primarily recurring single-use products, which represented approximately 79% of 2019 revenue. Product mix was 49% orthopedic surgery and 51% general surgery. The February 2019 acquisition of Buffalo Filter added smoke evacuation technologies to the general surgery portfolio.
Financial performance and key metrics
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Net sales | $955.1 million | $859.6 million | +11.1% |
| Gross profit | $524.7 million | $469.1 million | +11.9% |
| Gross margin | 54.9% | 54.6% | +0.3 percentage points |
| Income from operations | $79.1 million | $71.3 million | +11.0% |
| Operating margin | 8.3% | 8.3% | Flat |
| Interest expense | $42.7 million | $20.7 million | +106.8% |
| Net income | $28.6 million | $40.9 million | -30.0% |
| Diluted EPS | $0.97 | $1.41 | -31.2% |
| Operating cash flow | $95.1 million | $74.7 million | +27.4% |
| Capital expenditures | $20.1 million | $16.5 million | +21.6% |
Orthopedic surgery sales increased 3.7% to $463.3 million, while general surgery sales increased 19.1% to $491.8 million. Buffalo Filter contributed $49.6 million of 2019 sales. Constant-currency sales growth was 11.7%.
Selling and administrative expense increased to $400.1 million from $355.6 million, or 41.9% of sales versus 41.4%. Research and development expense increased to $45.5 million from $42.2 million but declined slightly as a percentage of sales to 4.8% from 4.9%.
The effective tax rate was 8.3% in 2019 versus 19.3% in 2018, primarily due to stock compensation tax benefits and the release of tax reserves following settlements with tax authorities. The lower tax rate partially offset the effect of higher interest and acquisition-related costs on net income.
Liquidity, debt and capital allocation
- Cash and cash equivalents were $25.9 million at December 31, 2019, including approximately $20.2 million held by foreign subsidiaries.
- Total debt was approximately $768.8 million on the balance sheet, while the filing separately describes $820.1 million of debt outstanding for leverage purposes. Investors should reconcile these amounts to the debt footnote and covenant calculations.
- The Company had $255.1 million outstanding under its term loan and $220.0 million under its revolving facility. Revolving availability was $362.5 million, with approximately $2.5 million reserved for letters of credit.
- The Company issued $345.0 million of 2.625% convertible notes due 2024 and entered into related note hedge and warrant transactions. The initial conversion price was approximately $88.80 per share; the hedge strike price was $114.92.
- Debt maturities include $418.8 million in 2023 and $345.0 million in 2024. Contractual obligations totaled $917.5 million, excluding periodic interest payments.
- Management stated that operating cash flow, cash on hand and available borrowing capacity should meet anticipated working capital, debt service, capital expenditure, dividend and repurchase needs in the foreseeable future.
- The Company paid $22.6 million in dividends during 2019 and maintained a quarterly dividend of $0.20 per share. No shares were repurchased during 2019; $37.4 million remained under the authorized repurchase program.
Material changes versus the prior comparable period
- The Buffalo Filter acquisition closed on February 11, 2019 for approximately $365 million in cash. The transaction added $215.8 million of goodwill and $140.0 million of identifiable intangible assets, including $124.0 million of customer relationships.
- Net sales and operating income increased, but net income and EPS declined because of higher interest expense, amortization associated with acquired intangible assets, acquisition costs and refinancing costs.
- Interest expense more than doubled because of additional borrowings and the convertible notes. Other expense included approximately $3.6 million of lender commitment fees and a $0.3 million loss on early extinguishment of debt.
- Acquisition and other costs included $13.1 million of Buffalo Filter-related costs in selling and administrative expense, $1.3 million of acquisition-related cost of sales, and $2.9 million of manufacturing consolidation costs.
- Net cash used in investing activities increased to $387.7 million from $16.5 million, principally because of the Buffalo Filter purchase. Financing activities provided $300.9 million, compared with a $72.3 million use of cash in 2018.
- Fourth-quarter 2019 net sales were $264.9 million and net income was $14.9 million, compared with $242.4 million and $15.7 million, respectively, in the fourth quarter of 2018. Fourth-quarter 2019 included $1.9 million of acquisition costs and $1.4 million of manufacturing consolidation costs.
Guidance, outlook, commentary and risks
The filing does not provide explicit quantitative revenue or earnings guidance. Management described growth priorities including new product development, strategic acquisitions, manufacturing efficiencies and international expansion. Management also stated that liquidity is expected to be adequate for foreseeable operating and financing needs.
- Key operating risks include healthcare spending and reimbursement changes, competitive pricing pressure, customer purchasing patterns, raw-material availability and supplier concentration.
- Approximately 30% of products by revenue are sterilized using third-party ethylene oxide providers. Further capacity restrictions or facility closures could disrupt product availability.
- Approximately 46% of 2019 sales were to customers outside the United States, creating foreign-exchange, geopolitical, regulatory, tariff and economic risks. Currency movements reduced 2019 sales by approximately $4.9 million.
- Approximately $475.1 million of variable-rate long-term debt was outstanding at year-end. A 1.0 percentage-point increase in comparable interest rates was estimated to reduce pretax income by approximately $4.8 million.
- Debt covenants restrict certain acquisitions, dividends, additional debt and other activities. The Company was in compliance with its covenants at December 31, 2019.
- The convertible notes may require cash payments upon conversion and may create dilution through related warrants. The filing states that the average share price did not exceed the conversion price for full-year 2019, although diluted EPS included assumed shares in the third and fourth quarters.
- The Company disclosed pending litigation involving EndoDynamix, with a non-jury trial scheduled for July 2020. Management denied liability and did not expect pending claims to have a material adverse effect, but no assurance was given.
- Other risks include product recalls, regulatory enforcement, product liability and intellectual-property claims, cybersecurity breaches, allograft tissue availability, environmental obligations and acquisition integration.
- Management and the auditors concluded that internal control over financial reporting was effective as of December 31, 2019.
Important facts for investors to verify
- Reconcile reported debt of $768.8 million with the filing’s $820.1 million leverage disclosure and review the 2023-2024 maturity concentration.
- Assess whether Buffalo Filter’s sales growth and expected synergies offset acquisition-related amortization, integration costs and incremental interest expense.
- Review the valuation assumptions supporting the $124.0 million Buffalo Filter customer-relationship intangible asset and $215.8 million of goodwill.
- Monitor cash conversion, working-capital requirements and the Company’s ability to fund debt service, dividends and capital expenditures.
- Evaluate sensitivity to variable interest rates, foreign currency movements and the availability of ethylene oxide sterilization capacity.
- Review the EndoDynamix litigation, regulatory matters, product liability coverage and any developments affecting contingent liabilities.
- Confirm future quantitative guidance, if provided in subsequent filings or investor communications, because this Form 10-K does not include explicit financial guidance.